Veronika Sergeevna Shmigerova

Veronika Sergeevna Shmigerova

Auto-generated profile, based on publicly available information

Veronika Sergeevna Shmigerova

Belgorod State National Research University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
YSYulia V. Stepenko
Yulia V. Stepenko
VSVeronika S. Shmigerova
Veronika S. Shmigerova
DKDarya A. Kostina
Darya A. Kostina
OSOlesya Shcheblykina
Olesya Shcheblykina
NZNina I. Zhernakova
Nina I. Zhernakova
ABAnton A. Bolgov
Anton A. Bolgov
Introduction: Tau proteinopathy is a pathology associated with the activation of post-translational modifications and interactions of pathophysiological cascades of neuroinflammation with hyperphosphorylation of Tau aggregates. Therefore, preference is given to agents that have properties in reducing or slowing down the processes of neuroinflammation and post-translational modifications in the brain. Materials and Methods: The study was conducted on male and female homozygous individuals of a transgenic murine line with overexpression of mutant human Tau gene (P301S) and a background wild mouse line C57Bl/6J. To assess the progression of Tau proteinopathy, behavioral tests were used at two control time points, and the last one measured the level of neuroinflammation markers and tau-proteinopathy. Results and Discussion: In the group of P301S mice treated with ARA-290, an improvement in the phenotypic picture of Tau proteinopathy was demonstrated compared with intact animals. In the Barnes circular maze test, mice showed a decrease in the total distance traveled and the latent time spent on the platform, which indicates a rapid entry into the shelter. In the O-shaped maze test, the group maintained a fairly high level of spontaneous exploratory behavior. In the vertical rod test, the animals recorded the best time indicators that they needed to turn and maintain balance compared to the intact group. A statistically significant decrease in the level of GSK-3β and an increase in CDK5 and PP2A were revealed, which indicates a dephosphorylating effect on Tau protein, as well as markers of neuroinflammation. NF-KB and TNF-α were significantly reduced by 57% and 32%, respectively, compared to the intact group. Conclusion: In the model of transgenic P301S murine line with overexpression of the mutant human Tau gene, the peptide agonist of the EPOR/CD 131 heteroreceptor demonstrated neuroprotective properties, which were confirmed by indicators of behavioral tests and markers of neuroinflammation and tau-proteinopathy. Введение. Таупротеинпатия – патология, связанная с активацией посттранляционных модификаций и за счет взаимодействия патофизиологических каскадов нейровоспаления с гиперфосфорилированием агрегантов Тау. Поэтому отдают предпочтения агентам, у которых есть свойства снижать или замедлять процессы нейровоспаления и посттрансляционные модификации в головном мозге. Материалы и методы: исследование проведено на самцах и самках гомозиготных особей трансгенной линии мышей с гиперэкспрессией мутантного гена Тау человека (P301S) и фоновой дикой линии мышей C57Bl/6J. Для оценки прогрессирования таупротеинпатии применялись поведенческие тесты в двух контрольно-временных точках и на последней измерялся уровень маркеров нейровоспаления и таупротеинпатии. Результаты и их обсуждение: в группе мышей P301S с лечением при помощи ARA-290 продемонстрировала улучшение фенотипической картины таупротеинпатии по сравнению с интактными животными. В тесте круговой лабиринт Барнса у мышей зарегистрировали снижение общего расстояния пройденной дистанции и латентного времени нахождения на платформе, что говорит о быстром заходе в «убежище». В тесте О-образный лабиринт группа сохранила достаточно высокий уровень спонтанного исследовательского поведения. В тесте вертикальный стержень, у животных зарегистрированы лучшие показатели времени, которые им требовались для поворота и для удержания равновесия относительно интактной группы. Статистически значимое снижение уровня GSK-3β и увеличение CDK5 и PP2A, что говорит о дефосфорилирующем действии на белок Тау, а также маркеры нейровоспаления (NF-KB и TNF-α), которые были значительно снижены на 57% и 32% соответственно по сравнению с интактной группой соответственно. Заключение: пептидный агонист гетерорецептора EPOR/CD131 на модели трансгенной линии мышей P301S с гиперэкспрессией мутантного гена Тау человека обладает нейропротективными свойствами, что подтверждается в показателях поведенческих реакций и в определении маркеров нейровоспаления и таупротеинпатии.

25 February 2025 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
VSVeronika S. Shmigerova
Veronika S. Shmigerova
YSYulia V. Stepenko
Yulia V. Stepenko
AKAlexandra A. Kurbatova
Alexandra A. Kurbatova
NZNikita S. Zhunusov
Nikita S. Zhunusov
NLNikita S. Lyapkalov
Nikita S. Lyapkalov
TPTatiana G. Pokrovskaya
Tatiana G. Pokrovskaya
Introduction: Neurodegenerative diseases affecting neurons represent a wide spectrum of pathological conditions. To slow the accumulation of pathological tau protein, therapeutic interventions such as a pharmaceutical composition consisting of the tetrapeptide HAEЕ, zinc, and albumin may be employed. This composition possesses properties that can potentially slow disease progression. Materials and Methods: The experiment was performed on 60 homozygous mice of both sexes from a transgenic line with the overexpression of human mutant tau protein (P301S) and on 20 mice from a wild-type C57Bl/6J background line. Control groups (C57Bl/6J – K and P301S – K+) received NaCl injection water (100 µL subcutaneously, once every 2 days); the experimental group (P301S) received HAEE-Zn-HSA (75 mg/kg, 150 µL subcutaneously, once every 2 days); and the comparison group (P301S) received piracetam (1.75 g/kg, 175 µL subcutaneously, once every 2 days). Behavioral activity was analyzed using tests at two time points, and the phenotypic presentation and lifespan were evaluated. Results and Discussion: The P301S group of mice treated with HAEE-Zn-HSA at a dosage of 75 mg/kg showed positive behavioral activity in the following tests: Open Field, Novel Object Recognition, and Inverted grid test, indicating increased exploratory activity, and improved motor function and coordination in the mice of this group. Pharmacological intervention with HAEE-Zn-HSA in the experimental group of transgenic mice demonstrated positive results, as a statistically significant effect on lifespan and delayed onset of the phenotypic presentation of the disease was shown (24±2.14 weeks, p≤0.05). Conclusion: The pharmaceutical composition HAEE-Zn-HSA at a dosage of 75 mg/kg, using a model of homozygous mice from a transgenic line with overexpression of human mutant tau protein P301S, demonstrated high levels of adaptive and exploratory activity and improved motor function.

28 March 2024 in Genes & Cells
Verified
Journal Article
Open access
PDF file
AZAlexandra Sergeevna Zelentsova
Alexandra Sergeevna Zelentsova
ABAlina Yur'Evna Borisova
Alina Yur'Evna Borisova
VSVeronika Sergeevna Shmigerova
Veronika Sergeevna Shmigerova
MSMarina Yur'Evna Skorkina
Marina Yur'Evna Skorkina
ADAlexey Deykin
Alexey Deykin
BACKGROUND: Primary mixed culture of neurons is often used to evaluate the molecular mechanisms underlying neurodegenerative disorders. However, isolating cells from the brain is accompanied by profound changes in cell morphology, behavior, and metabolic rate due to enzymatic disintegration and microenvironmental changes in cells. In this regard, the mitochondrial basal respiration of neurons should be considered as an indicator of the formation of functional activity of the cell. AIM: To evaluate mitochondrial respiration in a primary mixed culture of hippocampal neurons at various stages of differentiation. METHODS: This study included mice of line CD-1 and was conducted in two series: the first studied the primary mixed embryonic culture on the 18th day of gestation (E18) and the second used the postnatal culture on the 2nd day after birth (P2). A Seahorse XF HS Mini (Agilent, USA) was used to measure the functional parameters of cell metabolism. The oxygen consumption rate was calculated based on the results of the mitochondrial respiration profile of the primary mixed culture built during its differentiation. RESULTS: On the 5th day of neuronal differentiation in the culture, maximum mitochondrial respiration was established both in the hippocampal culture obtained from embryos on the 18th day of gestation and in the culture taken from mice on the 2nd day after birth. As cells differentiated in culture from days 2 to 11, the substrate oxidation rate increased almost twofold in the culture of hippocampal neurons obtained from embryos, which increased the metabolic potential. CONCLUSION: The study results prove that the hippocampus can be used to study the role of mitochondria in neurogenesis.

29 October 2021 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
ADAlexey Deykin
Alexey Deykin
OSOlesya Shcheblykina
Olesya Shcheblykina
EPElena E. Povetka
Elena E. Povetka
PGPolina Alexandrovna Golubinskaya
Polina Alexandrovna Golubinskaya
VPVladimir Pokrovskii
Vladimir Pokrovskii
VYVladimir I. Yakushev
Vladimir I. Yakushev
Introduction: In this review, the analysis of technologies for obtaining biologically active proteins from various sources is carried out, and the comparative analysis of technologies for creating producers of biologically active proteins is presented. Special attention is paid to genetically modified animals as bioreactors for the pharmaceutical industry of a new type. The necessity of improving the technology of development transgenic rabbit producers and creating a platform solution for the production of biological products is substantiated. The advantages of using TrB for the production of recombinant proteins: The main advantages of using TrB are the low cost of obtaining valuable complex therapeutic human proteins in readily accessible fluids, their greater safety relative to proteins isolated directly from human blood, and the greater safety of the activity of the native protein. The advantages of the mammary gland as a system for the expression of recombinant proteins: The mammary gland is the organ of choice for the expression of valuable recombinant proteins because milk is easy to collect in large volumes. Methods for obtaining transgenic animals: The modern understanding of the regulation of gene expression and the discovery of new tools for gene editing can increase the efficiency of creating bioreactors for animals and help to obtain high concentrations of the target protein. The advantages of using rabbits as bioreactors producing recombinant proteins in milk: The rabbit is a relatively small animal with a short duration of gestation, puberty and optimal size, capable of producing up to 5 liters of milk per year per female, receiving up to 300 grams of the target protein.

30 September 2020 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
VBVeronika S. Belyaeva
Veronika S. Belyaeva
YSYulia V. Stepenko
Yulia V. Stepenko
ILIgor I. Lyubimov
Igor I. Lyubimov
AKAlexandr L. Kulikov
Alexandr L. Kulikov
ATAlesia A. Tietze
Alesia A. Tietze
AGAnastasia V. Gureeva
Anastasia V. Gureeva
Relevance: Cardiovascular diseases continue to be the leading cause of premature adult death. Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid accumulation and migration of immunocompetent cells into the vessel intima. Macrophages accumulate cholesterol forming foam cells – the morphological substrate of atherosclerosis in its initial stage. Inflammation and atherogenesis: Pro-inflammatory factors provoke oxidative stress, vascular wall damage and foam cells formation. Endothelial and mitochondrial dysfunction in the development of atherosclerosis: Endothelial mitochondria are some of the organelles most sensitive to oxidative stress. Damaged mitochondria produce excess superoxide and H2O2, which are the main factors of intracellular damage, further increasing endothelial dysfunction. Short non-hematopoietic erythropoietin-based peptides as innovative atheroprotectors: Research in recent decades has shown that erythropoietin has a high cytoprotective activity, which is mainly associated with exposure to the mitochondrial link and has been confirmed in various experimental models. There is also a short-chain derivative, the 11-amino acid pyroglutamate helix B surface peptide (PHBSP), which selectively binds to the erythropoietin heterodymic receptor and reproduces its cytoprotective properties. This indicates the promising use of short-chain derivatives of erythropoietin for the treatment and prevention of atherosclerotic vascular injury. In the future, it is planned to study the PHBSP derivatives, the modification of which consists in adding RGD and PGP tripeptides with antiaggregant properties to the original 11-member peptide.

24 April 2025 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
ADAnton P. Danilenko
Anton P. Danilenko
AKAlexey A. Khentov
Alexey A. Khentov
AKAlexey V. Kuznetsov
Alexey V. Kuznetsov
VSVeronika S. Shmigerova
Veronika S. Shmigerova
YSYulia V. Stepenko
Yulia V. Stepenko
LDLyudmila Danilenko
Lyudmila Danilenko
Introduction: N-acetyl-6-aminohexanoate (acexamic acid) and its derivatives are actively studied as promising compounds for the creation of new drugs, but their pharmacokinetic parameters and detailed mechanisms underlying a wide range of biochemical activities are still unclear. Materials and Methods: PASS Online, Molinspiration Property Calculation Service and OSIRIS Property Explorer were used for predictive analysis. To determine the molecular biomarkers of the N-acetyl-6-aminohexanoate derivative – 2-ethyl-6-methyl-3-hydroxypyridinium N-acetylhexanoic acid, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) parameters were predicted. Molecular docking was performed using GalaxyWEB Sagittarius service followed by evaluation of the results using RCSB Protein Data Bank and UniProt Consortium databases. Results: The study of the pharmacokinetic properties of 2-ethyl-6-methyl-3-hydroxypyridine N-acetyl-6-aminohexanoate revealed its potential suitability as a promising drug with high bioavailability. The highest degree of affinity is predicted with the eNOS center – binding energy from -7.2 to -8.3 kcal/mol; the VEGF center – binding energies from -6.1 to -7.7 kcal /mol, and the RANKL centre – binding energies from - 6.0 - 6,9 kcal mol. Conclusion: The results of predictor analysis and molecular docking suggest that the N-acetyl-6-aminohexanoate-2-ethyl-6-methyl-3-hydroxypyridinium derivative is a safe and promising compound. Potential biotargets include eNOS, VEGF, and RANKL.